Table 3.

All-cause mortality of women with incident breast cancer by patterns of use of hormone therapy before diagnosis

Hormone therapyNo. deathsRate ratio* (95% CI)Multivariate rate ratio*, (95% CI)
Never3,0091.00 (Reference)1.00 (Reference)
Any HT use9440.74 (0.69-0.80)0.81 (0.75-0.87)
    Former HT use4360.82 (0.74-0.91)0.87 (0.78-0.96)
    Current HT use5070.68 (0.61-0.75)0.75 (0.68-0.83)
Type of exclusive treatment
    Estrogen alone6100.76 (0.70-0.83)0.82 (0.75-0.90)
    EP1740.63 (0.53-0.73)0.68 (0.58-0.81)
    Other/unknown1600.83 (0.71-0.98)0.89 (0.76-1.04)
Former or current use by type of exclusive treatment
    Estrogen, former3120.79 (0.70-0.89)0.84 (0.74-0.94)
    Estrogen, current2980.73 (0.64-0.82)0.80 (0.71-0.91)
    EP, former440.97 (0.72-1.31)1.01 (0.75-1.37)
    EP, current1300.55 (0.45-0.66)0.61 (0.50-0.73)
Duration by type of exclusive treatment
    Estrogen, <5 y2510.78 (0.69-0.89)0.83 (0.72-0.94)
    Estrogen, ≥5 y3590.74 (0.67-0.83)0.82 (0.73-0.91)
    EP, <5 y1050.74 (0.61-0.91)0.80 (0.65-0.98)
    EP, ≥5 y690.49 (0.39-0.63)0.55 (0.43-0.71)
  • * Proportional hazards models stratified on state, year of interview, and age at diagnosis.

  • Proportional hazards models adjusted for BMI, mammography, smoking status and time from date of diagnosis to interview.

  • Reference category.